Vivus Inc. (NASDAQ:VVUS) whose share price is down sharply in the last 12-months due to the flawed launch of its obesity drug Qsymia, is looking to boost investor confidence with a successful launch for its new erectile dysfunction (ED) drug Stendra (branded as Spedra in Europe). VIVUS, Inc. (NASDAQ:VVUS) stock opened at $9.11 in last session, and closed at $9.18, while the day range of stock is $9.07 – $9.26. The stock showed a negative weekly performance of -3.87%.
Arena Pharmaceuticals (NASDAQ:ARNA) is marching upward, as scripts gain traction with the new year. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) stock opened at $6.15, in last session and closed at $6.37, by gaining 5.12%. The 52 week range of the stock is $4.05 – $11.00. Company’s market capitalization is $1.39 billion.
In Friday’s trading session there was a drop of 0.46% in Ariad Pharmaceuticals, Inc (NASDAQ:ARIA). Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) stock decreased -0.46% and finished the last session at $6.73. The EPS of the stock remained -1.46. Company’s market capitalization is $1.25 billion.
MannKind Corporation (NASDAQ:MNKD) lost 16.38% after the company disclosed that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) has tentatively scheduled a review of MannKind’s New Drug Application (NDA) for AFREZZA(R) Inhalation Powder on April 1, 2014. The FDA will confirm the date and details of the meeting in a Federal Register notice. MannKind Corporation (NASDAQ:MNKD) stock opened the session at $6.69, and closed the session at $5.92. The 52 week range of the stock remained $2.34 – $8.70 and the day range was $5.90 – $6.69.